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AbstrACt
Introduction Supervised community treatment (SCT) 
for people with serious mental disorders has become 
accepted practice in many countries around the world. 
In England, SCT was adopted in 2008 in the form of 
community treatment orders (CTOs). CTOs have been used 
more than expected, with significant variations between 
people and places. There is conflicting evidence about 
the effectiveness of SCT; studies based on randomised 
controlled trials (RCTs) have suggested few positive 
impacts, while those employing observational designs 
have been more favourable. Robust population-based 
studies are needed, because of the ethical challenges of 
undertaking further RCTs and because variation across 
previous studies may reflect the effects of sociospatial 
context on SCT outcomes. We aim to examine spatial 
and temporal variation in the use, effectiveness and 
cost of CTOs in England through the analysis of routine 
administrative data.
Methods and analysis Four years of data from the 
Mental Health Services Dataset (MHSDS) will be analysed 
using multilevel models. Models based on all patients 
eligible for CTOs will be used to explore variation in 
their use. A subset of CTO-eligible patients comprising 
a treatment group (CTO patients) and a matched control 
group (non-CTO patients) will be used to examine 
variation in the association between CTO use and 
study outcomes. Primary outcome will be total time in 
hospital. Secondary outcomes will include time to first 
readmission and mortality. Outputs from these models 
will be used to populate predictive models of healthcare 
resource use.
Ethics and dissemination Ethical approval has been 
granted by the National Health Service Data Access 
and Advisory Group and Warwick University. To ensure 
patient confidentiality and to meet data governance 
requirements, analyses will be carried out in a secure 
microdata laboratory using de-identified data. Study 
findings will be disseminated through academic channels 
and shared with mental health policy-makers and other 
stakeholders.
IntroduCtIon 
Community treatment orders (CTOs), a 
form of supervised community treatment 
(SCT), were introduced to the Mental Health 
Act (2007) (MHA) in England and Wales in 
2008 and allow certain patients detained in 
hospital to continue treatment in the commu-
nity following discharge under specific condi-
tions. To be eligible for a CTO, a patient must 
be detained in hospital under the MHA on a 
section that allows for compulsory treatment. 
The most common inpatient treatment orders 
are sections 3 and 37, the former being a civil 
order and the latter a forensic, court-imposed 
equivalent for mentally ill offenders. A CTO 
provides the clinical team the power to recall 
the patient to hospital after discharge.
At CTO initiation (the point of discharge 
from inpatient care), there are two manda-
tory conditions, namely that the person 
subject to a CTO makes themselves available 
strengths and limitations of this study
 ► This will be the largest and most complete study of 
its kind and the national representativeness of the 
study sample, deriving from routine clinical activity, 
is a major strength.
 ► The study design reflects the range of real-world 
settings in which mental health services are deliv-
ered and patients live in England.
 ► The use of multilevel models will allow us to esti-
mate variation in community treatment order (CTO) 
use and outcome at individual, area and service lev-
el and to establish who CTOs work for and in what 
circumstances.
 ► Study limitations include confounding by indication 
and bias arising from missing data within the routine 
administrative data source.
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for assessment for its renewal and (where necessary) to be 
seen by an approved second opinion doctor (SOAD) for 
the purposes of assessing proposed treatment plan should 
the patient lack capacity in respect of their treatment. 
Discretionary conditions can also be specified which most 
often include treatment (ie, medication) adherence and 
engagement with services (eg, attending for appoint-
ments with professionals). CTOs do not permit compul-
sory (ie, forcible) treatment in the community,1 but those 
who default from these conditions may be recalled to 
hospital for assessment if there are grounds to suspect 
deterioration in their mental health and/or risk to the 
patient or others. Where this assessment indicates the 
need for further treatment, the CTO is revoked and the 
original treatment order applies.
There were two motivations for introducing CTOs in 
England and Wales2: to reduce ‘revolving door’ admis-
sions associated with non-adherence with care by a small 
group of patients, and to allow treatment in the least 
restrictive setting, in accordance with the Human Rights 
Act (1988). While it was originally envisaged that around 
10% of eligible patients would be placed on CTOs, the 
figure is currently closer to 30%.3 Since more CTOs are 
issued than are ended each year, the number of patients 
subject to CTOs has increased over time. Almost five thou-
sand CTOs were issued in 2016–2017, with use varying 
between demographic groups: rates of CTO use for males 
(11.4 per 100 000 population) were almost twice the rate 
for females (6.6 per 100 000 population), and the rate for 
black and black British people (60.1 per 100 000 popu-
lation) was almost nine times the rate for those of white 
ethnicity (6.8 per 100 000 population).4 Use also varies 
between National Health Service (NHS) (provider) 
Trusts.5 6
SCT has been adopted in over 75 other jurisdictions 
around the world,7 although it is used differently in 
different places. This is highlighted by its different names, 
including ‘involuntary outpatient commitment’, ‘assisted 
outpatient treatment’, ‘supervised discharge’, ‘compul-
sory community treatment’ and ‘compulsory ambula-
tory treatment’.8 In some places, SCT is initiated only by 
courts, while elsewhere, as in England, it remains a matter 
exclusively for health and social care providers, although 
within a framework prescribed by statute and subject to 
legal review. There are also differences between coun-
tries in the organisation and funding of mental health 
services, including separation of inpatient from commu-
nity mental health teams and variations in the nature and 
availability of care for people with severe mental illness. 
Generalising findings between countries is therefore 
problematic.
Despite widespread use, SCT remains controversial. In 
part, this is because patients and carers see it as coercive, 
raising fears of negative effects on therapeutic relation-
ships.9 This disquiet has been heightened by conflicting 
research evidence about effectiveness.10 There have 
been only three randomised controlled trials of CTOs, 
two in the USA and one in the UK. None demonstrated 
significant benefit of CTOs in terms of hospital readmis-
sion, social functioning, quality of life, mental state or 
offending.11–13 Randomised trials of CTOs face particular 
ethical and practical challenges (including relatively brief 
duration of follow-up), and these limit their utility.14 In 
critically appraising the two US trials, Kisely et al high-
lighted small sample sizes, the court-imposed nature of 
compulsory community treatment and the exclusion of 
patients with a history of violence. The OCTET trial in 
England experienced several methodological limitations, 
including the involuntary nature of the control condition, 
high rates of non-participation and patients who moved 
between trial arms after randomisation.15–17
Apart from the inevitable unblinding of participants 
and clinicians, it is impossible to disentangle the effects 
of legal compulsion from the vigilance and intensive care 
associated with CTO implementation.8 Further trials of 
CTOs are unlikely, given ethical challenges inherent in 
randomising those who may lack insight, and who may 
be dangerous to themselves or others, to legal restriction 
versus truly voluntary care.18
The results of observational studies are less consis-
tent, with some showing decreased admission rates and 
reduced bed use among those subject to SCT, while others 
do not.2 8 10 14 19 After excluding uncontrolled studies, 
observational research is characterised by matched cohort 
designs and before and after studies, with outcomes 
generally (but not invariably) assessed over 2 years or less. 
More recently, findings have emerged which suggest that 
patients on CTOs may experience better physical health 
and reduced mortality.20 21
Population-based observational studies using routine 
clinical and administrative data allow analysis of variation 
in SCT use and outcome to be studied.10 22 We will use 
4 years of data from the Mental Health Services Dataset 
(MHSDS) to address the following aims: (1) to examine 
spatial and temporal variation in the use of CTOs; (2) 
to estimate associations between CTO use and patient 
outcomes; (3) to explore variation in these associations 
between patients, places and providers, establishing 
when, where and for whom CTOs may be effective and 
(4) to estimate the financial costs and benefits associated 
with CTOs.
MEthods And AnAlysIs
data sources and study outcomes
The use of CTOs in England is recorded as part of a 
mandatory administrative dataset, the MHSDS, formerly 
known as the Mental Health Minimum Dataset, and then 
the Mental Health and Learning Disabilities Dataset.23 
MHSDS collates monthly returns from health service 
providers on all patients in contact with secondary mental 
health services provided and/or funded by NHS England. 
This includes voluntary and involuntary inpatient treat-
ment, outpatient attendance, day treatment and other 
episodes of secondary mental healthcare.
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MHSDS data are based on spells of care for individual 
patients. Since 2011, the dates on which specific care 
spells start and end have been included. Care spell dates 
can therefore be used to determine duration of CTO use 
and hospital (re)admissions. Four years of MHSDS data 
will be used covering the period 2011/2012 to 2014/2015, 
hereafter referred to as the study period. MHSDS records 
contain a unique patient identifier code which will be 
used to link patient care spells across the study period. 
This identifier will also be used to link patient records to 
the Office for National Statistics (ONS) Mortality Data-
base, to ascertain patient deaths. Access to and linkage of, 
these different administrative data sets will be facilitated 
by the ESRC Administrative Data Research Network.
Covariates
MHSDS provides data on a range of patient character-
istics, including age, sex and ethnicity. Data on clinical 
characteristics are also available such as diagnosis, care 
clusters (groupings of patients with similar needs and 
problem severities)24 and Health of the Nation Outcome 
Scales (outcome ratings for a range of health and social 
domains).25 Additional patient characteristics such as 
marital, employment and accommodation status may be 
present in the dataset, although previous research noted 
high levels of missing data.26
MHSDS patient records also include several spatial/
service setting identifiers (table 1). These will be used to 
link patient records to data on factors shown by previous 
studies to influence mental health outcomes at local area 
and service provider level. Specifically, English Indices 
of Deprivation 2015 will provide information about local 
area socioeconomic characteristics while ONS 2011 
Census data will be used to characterise local popula-
tions, including through the use of population density 
and ethnic composition data.27 28
data analysis
As the overarching aim of the study is to examine spatial 
and temporal variation in CTO use and outcome, multi-
level models (MMs) will be used.29 MMs allow varia-
tion in outcomes to be apportioned to the appropriate 
spatial level (eg, between patients, local areas and service 
settings) as well as estimating associations with individual, 
area and service-level characteristics.30 Since the local 
areas that patients live in do not nest hierarchically within 
the health service settings where they receive care (and 
vice versa), cross-classified MMs  (CCMMs) will be used 
(figure 1).31
Analysis will be conducted in three stages. First, CCMMs 
based on all patients eligible for CTOs will be used to 
explore spatial and temporal variation in the use of CTOs. 
CTO use will be considered as a binary outcome (patients 
subject to a CTO during the study period vs those who 
were not) and analyses will be undertaken using logistic 
multilevel regression. Models will estimate the variation 
at each level in the risk of being on a CTO and assess the 
extent to which any variation in this outcome is associ-
ated with patient, local area and health service character-
istics. We will also investigate the duration of time spent 
subject to CTO (in days). Poisson/negative binomial link 
function CCMMs will be used and will include offset vari-
ables to take account of different observation times for 
patients.32
Next, to examine associations between CTO use 
and a range of outcomes, a cohort of patients will be 
Table 1 Spatial/service setting identifiers present in the 
Mental Health Services Dataset
Spatial/service setting 
identifier Description
Lower layer super output 
area
Local area of residence, based 
on 2001 Census boundaries, 
typically containing 672 
households and 1614 residents
General practitioner 
practice
Primary care provider
National Health Service 
and independent sector 
provider trust
Provider of secondary mental 
healthcare
Primary care trust Commissioner of secondary 
mental healthcare
Figure 1 An illustration of cross-classified multilevel data.
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constructed consisting of a treatment group (those who 
have been on a CTO) and a matched control group 
(those who are eligible but who have not been on a 
CTO). To prevent bias arising from secular changes in 
clinical practice, we will frequency match these groups 
according to the start date of the CTO (CTO group) and 
the end date of the CTO-eligible section of the MHA 
(non-CTO group), with tolerance limits determined 
after inspection of the data. As these dates are the point 
within the study period at which patients in both treat-
ment groups are discharged from hospital, they repre-
sent the index date for each arm of the study. Models 
based on the cohort of matched patients will be used to 
test associations between SCT use and patient outcomes: 
total time spent in hospital, time to first readmission and 
mortality. For total time spent in hospital, count models 
based on Poisson or negative binomial distributions will 
be estimated. For time to first readmission, discrete-time 
survival analysis models will be estimated. For mortality, 
binary response models based on the logistic distribution 
will be estimated. To control for confounding by indica-
tion, we will adjust analyses for the propensity of being 
placed on SCT,33 with propensity scores being modelled 
using the pool of available variables which will include 
age, sex, ethnicity, diagnosis and previous admissions 
(where known). CCMMs based on this cohort will be 
used to test for the overall ‘average’ effect of CTO on 
each of the study outcomes. The models will also assess 
whether there is significant spatial and temporal varia-
tion around these average effects and estimate the extent 
to which this is associated with patient, local area and 
health service characteristics, including the length of 
time that patients are on CTOs.
Finally, we will use outputs from our CCMMs to popu-
late predictive models of healthcare resource use incor-
porating the predicted impact of CTOs. We will model 
differences in treatments costs (eg, bed days and number 
of contacts with mental health staff) between patients 
who are and are not on CTOs. We will also quantify 
the administrative burden of CTOs, using protocols for 
mandated governance processes (eg, Mental Health Act 
Review Tribunals and SOADs) that apply to the use of 
CTOs. Projected costs associated with different plausible 
future trajectories of CTO use will be calculated and a 
probabilistic sensitivity analysis will be presented for each 
projection based on estimates of parameter uncertainty 
derived from the CCMMs.
CCMMs will be estimated in MLwIN using Markov 
chain Monte-Carlo (MCMC) Bayesian methods.34 This 
approach is suited to the complexity of the MHSDS and 
will provide unbiased measures of variation in CTO use 
and outcome, and associations with patient, local area 
and health setting characteristics. MCMC modelling 
diagnostics, together with measures of multilevel varia-
tion, will be used to evaluate different models to quan-
tify where, and for whom, associations and variation 
occurs.35–37
PAtIEnt And PublIC InvolvEMEnt
Two reference groups will provide guidance to the project 
to maximise its relevance and impact. The first group will 
consist of mental health service users and carers and will 
include people with lived experience of being subject to 
CTOs or of caring for someone who has. Participants will 
be recruited by the Mental Health Foundation, the largest 
mental health policy, research and service improvement 
charity in England. Recruitment will ensure diversity of 
age, gender and ethnicity. The second group will consist 
of mental health professionals and will include managers 
and clinicians. The reference groups will help us ensure 
that analyses and dissemination are relevant to the needs 
of stakeholders.
EthICs And dIssEMInAtIon
To ensure patient confidentiality and to meet data gover-
nance requirements, analyses will be carried out in a 
secure microdata laboratory at the ONS using de-iden-
tified data. Reporting of the study will be consistent with 
the Strengthening the Reporting of Observational Studies 
in Epidemiology guidelines.38
CTOs are used more often than originally anticipated 
in England. Although many clinicians continue to see 
their value,39 uncertainty and concern about their use has 
been expressed by regulators and legislators.3 40 Both have 
called for the sort of nuanced evidence about the benefits 
and hazards of CTO use in real-world settings which can 
only come from large-scale, population-based, observa-
tional research. The purposes of this study are to describe 
the practice in respect of CTO use and duration, to esti-
mate associations with, and spatial variation in, outcomes, 
and to understand where, and for whom, CTOs might 
be of benefit. We will also model the economic costs and 
benefits of current patterns of CTO use.
This will be the largest and most complete study of its 
kind in England. The national scope and representative-
ness of the study sample, deriving from routine clinical 
activity, is a major strength, as is the duration of follow-up. 
Study limitations are those that affect observational and 
secondary research, particularly confounding by indi-
cation, residual confounding and bias. Issues of data 
quality (including missing data) are important sources 
of the latter.41 The study findings will be of direct policy 
relevance, and we plan to share them directly with those 
bodies working in this area at the earliest opportunity.
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